Max Grogl
8Patents
3h-index
16Co-inventors
50Inventor score
Filing activity: Aug 15, 1985 → Mar 26, 1998
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5202320A | Method for treating leishmaniasis | Emerging Cross-Sectional Technologies | 7 | Expired |
| US4740456A | Immunological methods for diagnosing neurocysticercosis | Emerging Cross-Sectional Technologies | 6 | Expired |
| US5206236A | Method for the treatment of malaria | Emerging Cross-Sectional Technologies | 4 | Expired |
| US4801532A | Immunological methods for diagnosing neurocysticercosis | Emerging Cross-Sectional Technologies | 3 | Expired |
| US5281597A | Heterocyclic and aromatic thiosemicarbazones useful in the treatment of filariasis | Human Necessities | 2 | Expired |
| US6433023B1 | Compositions having anti-leishmanial activity | Emerging Cross-Sectional Technologies | 1 | Expired |
| US4855408A | Antigens for diagnosing neurocysticercosis | Emerging Cross-Sectional Technologies | 1 | Expired |
| US6284739A | Antileishmanial composition for topical application | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.